← Back to Clinical Trials
Recruiting Phase 1 NCT06376331

NCT06376331 Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06376331
Status Recruiting
Phase Phase 1
Sponsor The Second Hospital of Nanjing Medical University
Condition Attention-deficit/Hyperactivity Disorder
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-04-28
Primary Completion 2027-06-01

Trial Parameters

Condition Attention-deficit/Hyperactivity Disorder
Sponsor The Second Hospital of Nanjing Medical University
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 50
Sex ALL
Min Age 3 Years
Max Age 17 Years
Start Date 2024-04-28
Completion 2027-06-01
Interventions
washed microbiota transplantation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention and hyperactivity-impulsivity. ADHD is often accompanied by oppositional defiant disorder and sleep disturbance, and can increase the risk of other psychiatric disorders, functional impairment in academic and occupational performance. Recently, gut microbiota has been implicated in the ADHD via gut-brain axis. In this study, investigators aimed to evaluate the efficacy of WMT for core ADHD symptoms and its comorbidities using specialized questionnaires for ADHD and investigate the underlying mechanism.

Eligibility Criteria

Inclusion Criteria: 1. Children with an established diagnosis of ADHD according to Diagnostic And Statistical Manual Of Mental Disorders Fifth Edition; 2. Aged 3-17; 3. Received stable treatments for ≥1 month preceding WMT; 4. Did not take medications affecting gut microbiota such as antibiotics and probiotics three months before WMT. Exclusion Criteria: 1. Unable to understand the questionnaires or provide informed consent by the guardian; 2. Diagnosed with a single-gene disorder, psychosis, central nervous system diseases, gastrointestinal diseases including ulcerative colitis, Crohn's disease, celiac disease, or eosinophilic esophagitis; 3. Had severe comorbidities including cardiopulmonary failure, severe liver, and kidney diseases and cancer; 4. Accompanied with other life-threatening disorders required emergency treatment; 5. Unable to tolerate colonoscopy or anesthesia

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology